This is a first-in survivor, single-arm pilot study with the goal of establishing evidence of feasibility and safety of a combined pharmacologic (metformin) and lifestyle intervention (using an existing digital platform) to prevent diabetes in prediabetic adult survivors of childhood cancer. Primary Objective The primary aim of this proposal is to establish the feasibility and safety of a 24-week combined metformin + intensive lifestyle intervention among adult survivors with prediabetes (including a 12-week lifestyle alone run-in followed by 12-week combined intervention among survivors remaining prediabetic). Primary endpoints of this trial will be adherence to 1) daily metformin administration and 2) completion of required core-curriculum of the lifestyle change intervention. Safety will be assessed using the Global Rating of Side Effects Burden Secondary Objectives The secondary aim is to assess preliminary evidence for efficacy of the combined metformin + intensive lifestyle intervention on glycemic control and insulin resistance. Glycemic control will be measured by fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) and insulin resistance measured by the homeostatic model assessment (HOMA-IR) and IGF- binding protein 1 (IGF-BP1; a measure of insulin sensitivity strongly correlated with euglycemic insulin clamp testing). Exploratory Objectives To assess preliminary evidence for efficacy of the combined metformin + intensive lifestyle intervention on weight, other anthropometric measures, blood pressure and lipid profile, physical activity (self-reported and as measured by accelerometer), frailty measures, and health-related quality of life (HRQOL). We will also assess diabetes development at future SJLIFE visits. To assess measures of participation in the lifestyle change program as well as barriers to participation and medication adherence.
Age range
18 Years – 44 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Adherence for feasibility
Timeframe: 2 years
Digitally-delivered core education curriculum through the lifestyle change platform
Timeframe: At end of Week 24
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 4
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 8
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 12
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 14
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 16
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 20
Safety and Adverse Events (Symptom Log including monitoring for AEs)
Timeframe: Week 24
Drug adherence/Pill Counts
Timeframe: Week 2
Drug adherence/Pill Counts
Timeframe: Week 4
Drug adherence/Pill Counts
Timeframe: Week 8
Drug adherence/Pill Counts
Timeframe: Week 12
Drug adherence/Pill Counts
Timeframe: Week 16
Drug adherence/Pill Counts
Timeframe: Week 20
Drug adherence/Pill Counts
Timeframe: Week 24